The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's Net Margin % or its related term are showing as below:
SHPH's Net Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.69 * Ranked among companies with meaningful Net Margin % only.
Shuttle Pharmaceuticals Holdings (NAS:SHPH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shuttle Pharmaceuticals Holdings Net Margin % Related Terms
Shuttle Pharmaceuticals Holdings Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shuttle Pharmaceuticals Holdings Net Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shuttle Pharmaceuticals Holdings Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shuttle Pharmaceuticals Holdings (SHPH) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 953 companies in the Drug Manufacturers industry.
Is Shuttle Pharmaceuticals Holdings' Net Margin % too high?
Shuttle Pharmaceuticals Holdings' current Net Margin % is 0.00%. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' Net Margin % compare to PRFX and CBIH?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 953 companies for Net Margin %. This places Shuttle Pharmaceuticals Holdings in the lower half of its industry. The industry median Net Margin % is 5.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shuttle Pharmaceuticals Holdings Business Description
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score
Get the complete analysis for SHPH
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPH has been successfully added to your 
